(Prepared 14 April 2026) 1. Executive Summary VGD‑097 is a next‑generation small‑molecule inhibitor currently being advanced by Vanguard Therapeutics Ltd. (formerly known as Vanguard Bio‑Discovery). The compound belongs to a proprietary chemotype (the “VGD series”) that targets the RNA‑dependent RNA polymerase (RdRp) complex of several emerging RNA viruses, with a particular focus on the flavivirus and filovirus families. Early pre‑clinical data indicate nanomolar potency, a high barrier to resistance, and a favorable pharmacokinetic (PK) profile that supports once‑daily oral dosing.
VGD‑097’s unique binding mode circumvents the cross‑resistance seen with nucleoside analogues and offers a differentiated safety profile (no mitochondrial toxicity, negligible drug‑drug interaction potential). | Patent No. | Territory | Filing Date | Expiration | Claims | |------------|-----------|------------|------------|--------| | WO 2023/124567 | World (PCT) | 12 Jan 2023 | 2038 | Core VGD chemotype, allosteric RdRp binding pocket. | | US 11,987,321 | US | 05 Mar 2024 | 2044 | Specific substitution pattern at C‑4 of pyrimidine core; formulation. | | EP 4,567,891 | EU | 19 Jun 2024 | vgd-097
Inclusion : Confirmed EBOV infection (RT‑PCR Ct ≤ 30), ≤ 72 h from symptom onset, age 18‑65, no severe hepatic/renal failure. (Prepared 14 April 2026) 1